New hope for women battling tough ovarian cancer

NCT ID NCT05613088

Completed Disease control Sponsor: Bristol-Myers Squibb Source: ClinicalTrials.gov ↗

Summary

This study tested a new targeted drug called farletuzumab ecteribulin (MORAb-202) against standard chemotherapy for women with a specific, hard-to-treat form of ovarian cancer that had stopped responding to platinum-based drugs. The goal was to see if the new drug was safer and more effective at shrinking tumors. It involved 106 women and directly compared the two treatment approaches.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Locations

Local Institution - 0001

Madrid, M, 28041, Spain
Local Institution - 0002

Brescia, 25123, Italy
Local Institution - 0003

Bologna, BO, 40138, Italy
Local Institution - 0004

Kurume-Shi, 830-0011, Japan
Local Institution - 0005

Madrid, M, 28007, Spain
Local Institution - 0006

Valencia, V, 46010, Spain
Local Institution - 0007

Valencia, V, 46009, Spain
Local Institution - 0009

Milan, MI, 20141, Italy
Local Institution - 0010

Roma, RM, 00168, Italy
Local Institution - 0011

Milan, MI, 20132, Italy
Local Institution - 0012

Brussels, 1200, Belgium
Local Institution - 0013

Namur, WNA, 5000, Belgium
Local Institution - 0014

Hidaka-shi, 350-1298, Japan
Local Institution - 0015

Clayton, Victoria, 3168, Australia
Local Institution - 0016

Sydney, New South Wales, 2065, Australia
Local Institution - 0017

Waratah, New South Wales, 2298, Australia
Local Institution - 0018

Akashi, Hyogo, 673-8558, Japan
Local Institution - 0019

Chūōku, 104-0045, Japan
Local Institution - 0020

Girona, 17007, Spain
Local Institution - 0021

Barcelona, 08036, Spain
Local Institution - 0022

Madrid, 28046, Spain
Local Institution - 0023

Canton, Ohio, 44710-1702, United States
Local Institution - 0025

San Francisco, California, 94109, United States
Local Institution - 0027

Malvern, Victoria, 3144, Australia
Local Institution - 0029

Temuco, 4800827, Chile
Local Institution - 0030

Santiago, RM, 8420323, Chile
Local Institution - 0031

Chermside, Queensland, 4032, Australia
Local Institution - 0032

Leuven, VBR, 3000, Belgium
Local Institution - 0036

Santiago, 7510032, Chile
Local Institution - 0037

Tokyo, 135-8550, Japan
Local Institution - 0038

Madrid, 28033, Spain
Local Institution - 0039

Barcelona, B, 08035, Spain
Local Institution - 0042

Spokane, Washington, 99204, United States
Local Institution - 0043

Kansas City, Kansas, 66160, United States
Local Institution - 0044

Nashville, Tennessee, 37203-1625, United States
Local Institution - 0045

Liège, 4000, Belgium
Local Institution - 0046

Jerusaelm, JM, 9112001, Israel
Local Institution - 0048

Tel Aviv, 64239, Israel
Local Institution - 0049

Seoul, 03722, South Korea
Local Institution - 0053

Seoul, 5505, South Korea
Local Institution - 0054

Haifa, 31999, Israel
Local Institution - 0055

Ramat Gan, 5265601, Israel
Local Institution - 0056

Seoul, 03080, South Korea
Local Institution - 0058

Nedlands, Western Australia, 6009, Australia
Local Institution - 0061

Columbus, Ohio, 43219, United States
Local Institution - 0065

Sacramento, California, 95817, United States
Local Institution - 0078

Whittier, California, 90602-3171, United States
Local Institution - 0080

Jerusalem, 91031, Israel
Local Institution - 0081

South Bend, Indiana, 46601-1033, United States
Local Institution - 0082

Salt Lake City, Utah, 84124, United States

Conditions

Explore the condition pages connected to this study.

NEOPLASMS,OVARIAN